Dreamm-7: A Phase Iii Study Of The Efficacy And Safety Of Belantamab Mafodotin (Belamaf) With Bortezomib, And Dexamethasone (B-Vd) In Patients With Relapsed/Refractory Multiple Myeloma (Rrmm)

Introduction: Belantamab mafodotin (belamaf; GSK2857916) is a B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate. In the pivotal Phase II DREAMM-2 study, single-agent belamaf demonstrated deep and durable responses and a manageable safety profile in patients refractory and/or intolerant to ≥3 lines of therapy, including an anti-CD38 monoclonal antibody such as daratumumab (Lonial et al. Lancet Oncol 2020). Responses were sustained at 13 months of follow-up with belamaf (2.5 mg/kg intravenously [IV] every 3 weeks [Q3W]); overall response rate (ORR) was 32% and median duration of response (DoR) was 11.0 months (Lonial et al. ASCO 2020 Poster 436).